Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNF 180 Life Sciences	$3.30 -31.4%	$2.80	$0.66 ▼ $17.75	$19.93M	0.38	22.03 million shs	72.02 million shs
ENLV Enlivex Therapeutics	$1.05 +1.9%	$1.26	$0.81 ▼ $2.10	$24.83M	0.8	1.30 million shs	887,884 shs
SLGL Sol-Gel Technologies	$22.67 -12.1%	$10.98	$4.01 ▼ $26.89	$63.15M	1.21	24,984 shs	91,055 shs
SNSE Sensei Biotherapeutics	$8.04 +6.5%	$8.01	$5.00 ▼ $17.40	$10.04M	0.26	33,908 shs	10,826 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNF 180 Life Sciences	-31.39%	-53.13%	+54.93%	+250.28%	+72.77%
ENLV Enlivex Therapeutics	0.00%	-42.31%	-8.06%	+7.69%	-14.63%
SLGL Sol-Gel Technologies	0.00%	+46.83%	+104.05%	+198.68%	+277.83%
SNSE Sensei Biotherapeutics	0.00%	-7.37%	+12.29%	+36.04%	-34.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNF 180 Life Sciences	0.506 of 5 stars	0.0	2.0	0.0	2.9	1.7	0.0
ENLV Enlivex Therapeutics	3.3259 of 5 stars	3.7	5.0	0.0	2.9	0.8	0.6
SLGL Sol-Gel Technologies	0.7835 of 5 stars	0.0	3.0	0.0	3.1	1.7	0.0
SNSE Sensei Biotherapeutics	4.3053 of 5 stars	3.7	3.0	4.8	0.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	852.38% Upside
SLGL Sol-Gel Technologies	0.00	N/A	N/A	N/A
SNSE Sensei Biotherapeutics	3.33	Buy	$55.00	584.08% Upside

Current Analyst Ratings Breakdown

Latest SNSE, ENLV, SLGL, and ATNF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/14/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
8/5/2025	SNSE Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/29/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/12/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/2/2025	SNSE Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$100.00
5/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$2.91 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
SLGL Sol-Gel Technologies	$11.54M	5.48	N/A	N/A	$11.44 per share	1.98
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$21.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNF 180 Life Sciences	-$6.17M	-$15.07	N/A	∞	N/A	N/A	-141.25%	-80.77%	11/12/2025 (Estimated)
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
SLGL Sol-Gel Technologies	-$10.58M	-$1.23	N/A	N/A	N/A	-14.25%	-11.80%	-9.39%	N/A
SNSE Sensei Biotherapeutics	-$30.16M	-$21.31	N/A	N/A	N/A	N/A	-72.13%	-61.35%	N/A

Latest SNSE, ENLV, SLGL, and ATNF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/15/2025	Q2 2025	SLGL Sol-Gel Technologies	-$0.67	$4.17	+$4.84	$4.17	$2.86 million	$17.26 million
8/5/2025	Q2 2025	SNSE Sensei Biotherapeutics	-$6.20	-$3.91	+$2.29	-$3.91	N/A	N/A
7/23/2025	Q2 2025	ATNF 180 Life Sciences	N/A	-$0.30	N/A	-$0.30	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNF 180 Life Sciences	N/A	0.58	0.58
ENLV Enlivex Therapeutics	N/A	7.20	7.20
SLGL Sol-Gel Technologies	N/A	7.32	5.12
SNSE Sensei Biotherapeutics	N/A	7.64	7.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNF 180 Life Sciences	4.07%
ENLV Enlivex Therapeutics	1.02%
SLGL Sol-Gel Technologies	26.18%
SNSE Sensei Biotherapeutics	10.50%

Insider Ownership

Company	Insider Ownership
ATNF 180 Life Sciences	38.20%
ENLV Enlivex Therapeutics	12.28%
SLGL Sol-Gel Technologies	66.51%
SNSE Sensei Biotherapeutics	23.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNF 180 Life Sciences	7	6.04 million	3.73 million	No Data
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable
SNSE Sensei Biotherapeutics	40	1.26 million	968,000	Not Optionable

SNSE, ENLV, SLGL, and ATNF Headlines

Recent News About These Companies

Sensei Biotherapeutics Inc trading resumes

August 15, 2025 | msn.com

Sensei Biotherapeutics Inc trading halted, volatility trading pause

August 15, 2025 | msn.com

Sensei (SNSE) Q2 Loss Narrows 31%

August 6, 2025 | fool.com

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025 | globenewswire.com

These 3 health tech stocks spiked 37% in a day; Time to buy?

August 4, 2025 | finbold.comF

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

July 30, 2025 | globenewswire.com

Sensei Biotherapeutics to execute 1-for-20 reverse stock split

June 13, 2025 | kalkinemedia.comK

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

June 13, 2025 | globenewswire.com

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

May 6, 2025 | globenewswire.com

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

April 2, 2025 | globenewswire.com

Sensei Biotherapeutics announces initial results from solnerstotug trial portion

March 29, 2025 | markets.businessinsider.com

Sensei Rockets on FY ’24 Results

March 28, 2025 | baystreet.ca

Sensei Rockets on FY ’24 Results

March 28, 2025 | baystreet.ca

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer

March 28, 2025 | markets.businessinsider.com

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer

March 28, 2025 | markets.businessinsider.com

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

March 28, 2025 | globenewswire.com

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

March 27, 2025 | globenewswire.com

What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock

February 6, 2025 | zacks.com

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | markets.businessinsider.com

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE, ENLV, SLGL, and ATNF Company Descriptions

180 Life Sciences NASDAQ:ATNF

$3.30 -1.51 (-31.39%)

As of 08/22/2025

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Enlivex Therapeutics NASDAQ:ENLV

$1.05 +0.02 (+1.94%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.03 -0.02 (-1.43%)

As of 08/22/2025 07:57 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies NASDAQ:SLGL

$22.67 -3.13 (-12.13%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$22.20 -0.47 (-2.07%)

As of 08/22/2025 07:39 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Sensei Biotherapeutics NASDAQ:SNSE

$8.04 +0.49 (+6.49%)

Closing price 08/22/2025 03:54 PM Eastern

Extended Trading

$8.39 +0.35 (+4.35%)

As of 08/22/2025 04:04 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time